Neoplasms by Histologic Type: Clinical Trials

43,420 trials for Neoplasms by Histologic Type, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18611 completed, 6485 recruiting, 6158 unknown, 4906 terminated. 17954 Phase 2, 11615 Phase 1, 5404 Not applicable, 3937 Phase 3, 842 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217954Completed 7712, Terminated 2501, Recruiting 2500, Unknown 2197, Active not recruiting 1399, Withdrawn 766, Not yet recruiting 745, Suspended 92, Enrolling by invitation 42
Phase 111615Completed 5159, Terminated 1877, Recruiting 1644, Unknown 1057, Active not recruiting 874, Withdrawn 550, Not yet recruiting 336, Suspended 94, Enrolling by invitation 24
Not applicable5404Completed 2086, Unknown 1026, Recruiting 996, Terminated 386, Not yet recruiting 357, Active not recruiting 277, Withdrawn 212, Enrolling by invitation 38, Suspended 26
Phase 33937Completed 1701, Unknown 624, Recruiting 537, Terminated 400, Active not recruiting 377, Not yet recruiting 158, Withdrawn 114, Suspended 14, Enrolling by invitation 12
Early Phase 1842Completed 222, Recruiting 162, Unknown 153, Terminated 103, Not yet recruiting 83, Active not recruiting 58, Withdrawn 49, Suspended 9, Enrolling by invitation 3
Phase 4761Completed 329, Unknown 208, Recruiting 76, Terminated 54, Not yet recruiting 41, Active not recruiting 26, Withdrawn 22, Enrolling by invitation 5

Follow Neoplasms by Histologic Type: new trials by email Literature Review of Neoplasms by Histologic Type trials Research Report on Neoplasms by Histologic Type

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-05-27
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
RNS System Implantation - Glioma, Glioma Intracranial
Not applicableNot yet recruitingMedical College of Wisconsin32028-08-012026-10-13
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingGerman Cancer Research Center122028-01-012025-03-14
Methadone as an Alternative Treatment for Children Underdoing HSCT
PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia
Phase 3SuspendedUniversity of Texas Southwestern Medical Center602028-01-012025-10-23
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center582027-12-012026-08-25
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Not applicableEnrolling by invitationOhio State University Comprehensive Cancer Center122027-10-012026-10-13
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse
Phase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine842027-10-012026-07-16
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma
Not applicableNot yet recruitingJonsson Comprehensive Cancer Center1002027-09-022026-10-19
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2Not yet recruitingCity of Hope Medical Center442027-08-042026-09-10
Residual IDH1-Mutant Tumor Cell Quantification Study
UR-ddPCR - Glioma
Not applicableNot yet recruitingNYU Langone Health1052027-08-012026-09-29
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Astragalus, Placebo - High-grade Lymphoma
Phase 3Not yet recruitingBnai Zion Medical Center602027-08-012026-09-30
CAR-T Immunotherapy Targeting CD19- ALL
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-07-012026-08-26

Showing 20 of 43420. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3659)  ·  Leukemia, Myeloid, Acute (3581)  ·  Carcinoma, Hepatocellular (3372)  ·  Melanoma (3198)  ·  Lymphoma (3015)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2520)  ·  Leukemia (2378)  ·  Lymphoma, Non-Hodgkin (2287)  ·  Neoplasms (2147)  ·  Glioblastoma (2068)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2018)  ·  Carcinoma, Renal Cell (1956)  ·  Squamous Cell Carcinoma of Head and Neck (1946)  ·  Recurrence (1900)  ·  Lymphoma, Follicular (1874)

Broader conditions

Neoplasms (41273)  ·  Neoplasms by Site (19033)  ·  Neoplasms, Glandular and Epithelial (18771)  ·  Hemic and Lymphatic Diseases (18036)  ·  Immune System Diseases (14233)  ·  Immunoproliferative Disorders (13924)  ·  Lymphoproliferative Disorders (13826)  ·  Carcinoma (13204)  ·  Hematologic Diseases (12020)  ·  Lymphatic Diseases (11234)  ·  Neoplasms, Nerve Tissue (8897)  ·  Neoplasms, Germ Cell and Embryonal (8647)  ·  Neuroectodermal Tumors (8496)  ·  Pathological Conditions, Signs and Symptoms (7969)

Interventions

Cyclophosphamide (2263)  ·  Rituximab (1450)  ·  Dexamethasone (1399)  ·  Radiotherapy (1286)  ·  Cisplatin (1279)  ·  pembrolizumab (1136)  ·  Cytarabine (1120)  ·  Doxorubicin (1002)  ·  Etoposide (938)  ·  Vincristine (922)  ·  fludarabine (892)  ·  Lenalidomide (891)  ·  Carboplatin (884)  ·  Nivolumab (877)  ·  Gemcitabine (816)

Sponsors

National Cancer Institute (NCI) (1896)  ·  M.D. Anderson Cancer Center (1209)  ·  Memorial Sloan Kettering Cancer Center (725)  ·  Sun Yat-sen University (554)  ·  Novartis Pharmaceuticals (468)  ·  Mayo Clinic (379)  ·  Children's Oncology Group (362)  ·  Dana-Farber Cancer Institute (322)  ·  Pfizer (298)  ·  City of Hope Medical Center (288)  ·  Fred Hutchinson Cancer Center (282)  ·  Bristol-Myers Squibb (272)  ·  Hoffmann-La Roche (266)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (256)  ·  Washington University School of Medicine (244)

Countries

United States (21190)  ·  China (6814)  ·  France (4151)  ·  Italy (3121)  ·  Canada (2875)  ·  Germany (2853)  ·  United Kingdom (2667)  ·  Spain (2616)  ·  Australia (1988)  ·  South Korea (1774)  ·  Netherlands (1627)  ·  Belgium (1529)  ·  Poland (1169)  ·  Japan (1109)  ·  Taiwan (1103)

Results publications

PMID 34515338, PMID 31401903, PMID 41671463, PMID 37146227, PMID 32499241, PMID 35622074, PMID 40135712, PMID 32632956, PMID 40812353, PMID 36648215, PMID 37185961, PMID 30207593, PMID 34398557, PMID 31150573, PMID 33538338, PMID 12049862, PMID 25057165, PMID 25667295, PMID 27238653, PMID 28410911, PMID 32827353, PMID 33394722, PMID 40550489, PMID 24383844, PMID 25527568, PMID 29433850, PMID 33242441, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 11981766, PMID 19097774, PMID 19192962, PMID 20375404, PMID 23524640, PMID 26373676, PMID 28054442, PMID 31221778, PMID 31395089, PMID 35235189, PMID 35829925, PMID 36064577, PMID 36184192, PMID 37022569, PMID 37192741, PMID 37505794, PMID 38620092, PMID 12540794, PMID 18650514

NIH funding

2023 (356), 2018 (206), P30CA033572 (200), 2016 (197), 2017 (184), 2015 (182), 2019 (178), U10CA032102 (175), 2014 (163), 2025 (149), P30CA015704 (148), P30CA015083 (141), 2009 (136), P30CA016672 (125), U10CA098543 (124)